RESEARCH: CANCER
FOLDING PROJECT #16469 PROFILE

Scientists are using computer simulations to understand how drugs block RIPK2, a protein involved in cancer growth. These simulations will show exactly how the drugs work and help us design better cancer treatments.

Kinases are a major target for a variety of cancer therapies, but their mechanism of action is relatively unknown at a detailed atomic level, preventing us from understanding and optimizing known inhibitors.

One example is the Serine/Threonine Kinase RIPK2.

RIPK2 inhibition is useful for cancer targeting as it prevents RIPK2 from binding a protein partner named XIAP.

In fact, there are already 3 known inhibitors that bind to RIPK2 and prevent RIPK2-XIAP binding! However, it remains difficult to optimize these ligands for clinical purposes because we do not understand how any of these three inhibitors actually act on RIPK2 to prevent XIAP binding behavior.

These four projects are simulating RIPK2 by itself and bound to each of the three inhibitors, with the hope that this will reveal a more detailed mechanism of how each inhibitor works to prevent XIAP binding.

As a bonus, this will help reveal how RIPK2 *binds* XIAP (also unknown)!.

Kinases

Enzymes that add phosphate groups to molecules.

Kinases are a crucial type of enzyme that plays a significant role in regulating various cellular processes. They work by attaching phosphate groups to other molecules, which can alter their activity and function. In cancer research, kinases are often targeted as potential drug targets because their dysregulation can contribute to tumor growth and spread.

RIPK2

Receptor-interacting protein kinase 2

RIPK2 is a protein involved in signaling pathways that regulate inflammation and cell death. It plays a role in the immune response and has been implicated in cancer development. Inhibition of RIPK2 has emerged as a potential therapeutic strategy for certain types of cancer.

XIAP

X-linked inhibitor of apoptosis protein

XIAP is a protein that inhibits programmed cell death (apoptosis). It plays a role in protecting cells from death signals. In cancer cells, XIAP overexpression can contribute to their survival and resistance to therapy. Targeting XIAP has been explored as a strategy to overcome drug resistance in cancer.

Inhibitors

Molecules that block or reduce the activity of a target.

Inhibitors are substances that can bind to and block the function of specific molecules, such as enzymes, receptors, or proteins. They play a crucial role in drug development, as many medications work by inhibiting the activity of disease-causing targets.

Ligands

Molecules that bind to a specific receptor or protein.

Ligands are molecules that can interact with and bind to specific receptors or proteins. This binding can trigger a variety of cellular responses, such as signal transduction or gene expression. In drug development, ligands are often designed to mimic the natural molecules that bind to target receptors.